Patents Examined by William Sandals
  • Patent number: 6159443
    Abstract: A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations thereof, exposing the target tissue to the ionizing radiation. The delivery vehicle includes the active agent and delivers the agent to the target tissue. Exemplary delivery vehicles include platelets; leukocytes; proteins or peptides which bind activated platelets; antibodies which bind activated platelets; microspheres coated with proteins or peptides which bind activated platelets; liposomes conjugated to platelets, leukocytes, proteins or peptides which bind activated platelets, or antibodies which bind activated platelets; and combinations thereof.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: December 12, 2000
    Assignee: Vanderbilt University
    Inventor: Dennis E. Hallahan
  • Patent number: 6156497
    Abstract: A method for generating adenoviral vectors from polynucleotides such as plasmids wherein there occurs recombinase-mediated transfer of an adenoviral ITR and terminal proteins bound to the ITR to a plasmid, thus enabling the plasmid to replicate as an adenoviral vector. Such method enables the rapid generation of adenoviral vectors at high titers from plasmids without the use of selectable markers and screening procedures. Such method enables the rapid generation of adenoviral vectors devoid of adenovirus backbone genes. The method also may be employed to generate hybrid adenoviral-retroviral vectors that convert transduced cells into producer cells that produce retroviral vectors to effect high level, permanent genetic modification of cells in vivo.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: December 5, 2000
    Assignee: Genetic Therapy, Inc.
    Inventor: Michael Kaleko
  • Patent number: 6156309
    Abstract: Insect viruses capable of killing at least one target insect pest quicker than previously described viruses and methods for conferring that phenotype of faster killing are provided. Further improvement in the speed of killing is obtained when the virus of this invention also contains a nonfunctional egt gene to reduce feeding by the infected larvae, inhibit growth and further mediate the earlier death of the infected insect and/or it also contains and expresses a DNA sequence encoding an insect-specific toxin. The faster killing phenotype is achieved by inactivating an ORF 603 of AcMNPV or an ORF 603 homolog of a different species of baculovirus. Improved insecticidal compositions and improved methods of controlling insects are also included within the scope of this invention.
    Type: Grant
    Filed: January 12, 1999
    Date of Patent: December 5, 2000
    Assignees: University of Georgia Research Foundation, American Cyanamid Corporation
    Inventors: Lois K. Miller, Bruce C. Black, Peter M. Dierks, Nancy C. Fleming
  • Patent number: 6143557
    Abstract: Recombinational cloning is provided by the use of nucleic acids, vectors and methods, in vitro and in vivo, for moving or exchanging segments of DNA molecules using engineered recombination sites and recombination proteins to provide chimeric DNA molecules that have the desired characteristic(s) and/or DNA segment(s).
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: November 7, 2000
    Assignee: Life Technologies, Inc.
    Inventors: James L. Hartley, Michael A. Brasch
  • Patent number: 6143501
    Abstract: The invention relates to new artificial tissues which comprise three-dimensional extracellular matrixes (ECM) in cross-linkable structures, cell interaction systems for inducing artificial three-dimensional tissues and which comprise genetically manipulated cells releasing immunosuppressive or cell-differentiating factors. The tissues according to the invention are suitable for producing vital transplants and for establishing models of diseases.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: November 7, 2000
    Inventors: Michael Sittinger, Olaf Schultz, Gerd R. Burmester, Thomas E. M. Haupl
  • Patent number: 6140104
    Abstract: The invention relates to sequences of nucleotides of bacteria, particularly Gram positive bacteria such as bacteria of the Bacillus type and more particularly sequences of nucleotides of the gene CryIIIA for the control of the expression of DNA sequences in a cellular host. The invention relates particularly to an expression system comprising a DNA sequence susceptible of being involved in the control of the expression of a coding sequence of nucleotides. Said DNA sequence comprises a promoter, as well as a sequence of nucleotides called "downstream region", situated between the promoter and the coding sequence of the gene to be expressed, and susceptible of acting at the post-transcriptional level during the expression of the gene. Preferably, the downstream region comprises a nucleotide sequence S2 comprising an essentially complementary region at the extremity 3' of the RNA 16S of the ribosomes of Bacillus type bacteria.
    Type: Grant
    Filed: December 20, 1995
    Date of Patent: October 31, 2000
    Assignees: Institut Pasteur, Institut Nationale de la Recherche Agronomique
    Inventors: Didier Lereclus, Herve Agaisse
  • Patent number: 6136566
    Abstract: Methods and vectors (both DNA and retroviral) are provided for the construction of a Library of mutated cells. The Library will preferably contain mutations in essentially all genes present in the genome of the cells. The nature of the Library and the vectors allow for methods of screening for mutations in specific genes, and for gathering nucleotide sequence data from each mutated gene to provide a database of tagged gene sequences. Such a database provides a means to access the individual mutant cell clones contained in the Library. The invention includes the described Library, methods of making the same, and vectors used to construct the Library. Methods are also provided for accessing individual parts of the Library either by sequence or by pooling and screening. The invention also provides for the generation of non-human transgenic animals which are mutant for specific genes as isolated and generated from the cells of the Library.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: October 24, 2000
    Assignee: Lexicon Graphics Incorporated
    Inventors: Arthur Sands, Glenn Friedrich, Brian Zambrowicz, Allan Bradley
  • Patent number: 6132776
    Abstract: Methods and compositions related to HIV are disclosed. Using the methods of the present invention, nucleoside analogs may be screened for the ability to be incorporated by reverse transcriptase of human immunodeficiency virus ("HIV RT") and cause incorrect base pairing. Progressive mutation of the virus by such nucleoside analogs renders it non-viable.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: October 17, 2000
    Assignee: University of Washington
    Inventors: Lawrence A. Loeb, John M. Essigmann
  • Patent number: 6133038
    Abstract: The invention provides platinum-based probe compounds having the structure: ##STR1## wherein: Pt is a platinum atom, PROBE is a probe biomolecule for associating to a target biomolecule, M is a detectable marker moiety, and X and Y are stabilizing substituents. Also provided are platinum-based labeling compounds having the structure: ##STR2## wherein: Pt is a platinum atom, M is a detectable marker moiety, A is a displaceable leaving group, and X and Y are stabilizing substituents. The invention further provides platinum-based linker compounds having the structure: ##STR3## wherein: Pt is a platinum atom, A and B are the same or different reactive moieties, and X and Y are stabilizing substituents. Other Pt.sup.II and Pt.sup.IV compounds are also provided. Moreover, the invention provides methods for the preparation and use of these compounds, as well as diagnostic kits which contain the compounds.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: October 17, 2000
    Assignee: Kreatech Diagnostics
    Inventors: Hendrik J. Houthoff, Jan Reedijk, Tinka Jelsma, Remco Maria Van Es, Franciscus Michiel van den Berg, Edwin Leo Mario Lempers, Marieke Johanna Bloemink
  • Patent number: 6110703
    Abstract: The present invention relates to a novel method for the production of short chain polypeptides, including polypeptides having up to 3 disulfide bonds and/or structures rich in basic amino acid residues, and open structured short chain polypeptides, e.g. glucagon, glucagon like peptides and their functional analogues, in genetically modified yeast cells, said genetically modified yeast cells, and a method for the preparation of said yeast cells.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: August 29, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Michi Egel-Mitani, Jakob Brandt, Knud Vad
  • Patent number: 6110736
    Abstract: DNA constructs and methods for conducting site-specific recombination in plants is described. The method utilizes FLP recombinase to excise a region of DNA flanked by a pair of directly repeated site-specific recombination sequences which are capable of interacting with a FLP recombinase.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: August 29, 2000
    Assignee: Purdue Research Foundation
    Inventors: Thomas K. Hodges, Leszek A. Lyznik
  • Patent number: 6100043
    Abstract: Cloning systems useful for the isolation of recombinant nucleic acid are disclosed in which the recombination of cloning-system nucleic acid and foreign nucleic acid is linked to the expression of a moiety on the surface of a host organism, the moiety being a first member of a binding pair. When recombination occurs between the nucleic acid and the foreign nucleic acid, the moiety is expressed on the surface of the host organism. The isolation of recombinant nucleic acid is then performed by attaching a second member of the binding pair to a solid support and contacting the host organism with the support. When the first member of the binding pair is expressed on the surface of the host organism, the host organism binds to the second member of the binding pair attached to the solid support, thereby selectively isolating those organisms.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: August 8, 2000
    Assignee: The Perkin-Elmer Corporation
    Inventors: John A. Bridgham, John Brandis, John Leong, Paul D. Hoeprich, Jr., Charles L. Sloan, Roger A. O'Neill
  • Patent number: 6096505
    Abstract: A noncloning method for expressing a gene of interest in a mammalian host cell is disclosed. The invention utilizes three basic individual elements: (1) a promoter element; (2) at least one gene of interest; and (3) a selectable marker cassette which includes in 5' to 3' order, an internal ribosome entry site ("IRES"), at least one gene coding for a selectable marker, and a transcription termination sequence. The three individual elements are cotransfected into a mammalian host cell where they become operably linked such that expression of the selectable marker gene(s) necessarily requires coexpression of the gene of interest.
    Type: Grant
    Filed: April 13, 1999
    Date of Patent: August 1, 2000
    Assignee: Chiron Corporation
    Inventors: Mark Selby, Kent B. Thudium, Dino Dina
  • Patent number: 6093542
    Abstract: An isothermal transcription based amplification assay for MDC RNA uses primer combinations for sequences within the MDC gene. A quantitative control uses a mutant RNA for comparison.
    Type: Grant
    Filed: January 9, 1998
    Date of Patent: July 25, 2000
    Assignee: Akzo Nobel N.V.
    Inventors: Joseph Romano, Ranajit Pal, Roxanne Shurtliff
  • Patent number: 6090542
    Abstract: Inhibition of the transcription of genes in higher eukaryotic cells by inhibiting the activation of NF-KB, wherein the cells are treated with substances which specifically inhibit the proteolytic degradation of IKB-.alpha. directly or indirectly. Process for screening substances which inhibit NF-KB activation by inhibiting the proteolytic degradation of IKB-.alpha.. Use of the substances for treating pathological conditions which can be traced back to undesirable gene expression controlled by NF-KB.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: July 18, 2000
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Patrick Baeuerle, Thomas Henkel
  • Patent number: 6090562
    Abstract: Cloning systems useful for the isolation of recombinant nucleic acid are disclosed in which the recombination of cloning-system nucleic acid and foreign nucleic acid is linked to the expression of a moiety on the surface of a host organism, the moiety being a first member of a binding pair. When recombination occurs between the nucleic acid and the foreign nucleic acid, the moiety is expressed on the surface of the host organism. The isolation of recombinant nucleic acid is then performed by attaching a second member of the binding pair to a solid support and contacting the host organism with the support. When the first member of the binding pair is expressed on the surface of the host organism, the host organism binds to the second member of the binding pair attached to the solid support, thereby selectively isolating those organisms.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: July 18, 2000
    Assignee: The Perkin-Elmer Corporation
    Inventors: John A. Bridgham, John Brandis, John Leong, Paul D. Hoeprich, Jr., Charles L. Sloan, Roger A. O'Neill
  • Patent number: 6084068
    Abstract: The functional domains of Elongin A having transcriptional activation activity and Elongin BC binding activity and the functional domains of Elongin C having Elongin A activation activity and Elongin A and/or Elongin C binding activity have now been identified and isolated.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: July 4, 2000
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Ronald C. Conaway, Joan W. Conaway
  • Patent number: 6083692
    Abstract: Methods of detecting the presence of linear DNA in a sample that contains circular DNA are disclosed. The methods comprise combining an ATP-dependent deoxyribonuclease, ATP and a sample to form a reaction mixture, maintaining the reaction mixture under conditions in which linear DNA is processed by the ATP-dependent deoxyribonuclease, and detecting the presence of ADP thus produced. Methods of detecting the presence of DNA, RNA, or protein in samples are disclosed. The methods comprise combining an ATP-dependent deoxyribonuclease, an ATP-dependent ribonuclease, or an ATP-dependent protease, respectively, with ATP and a sample to form a reaction mixture. The reaction mixture is maintained under conditions in which DNA, RNA or protein is processed by the respective ATP-dependent enzyme. The presence of ADP thus produced is detected, indicating the presence of the enzyme substrate. Methods of quantifying the DNA molecules, RNA molecules or protein molecules are also disclosed.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: July 4, 2000
    Assignee: American Home Products Corporation
    Inventors: C. Satishchandran, Manoj Samuel
  • Patent number: 6077667
    Abstract: The present invention involves the creation of defined chromosomal deficiencies, inversions and duplications using Cre recombinase in ES cells transmitted into the mouse germ line. These chromosomal reconstructions can extend up to 3-4 cM. Chromosomal rearrangements are the major cause of inherited human disease and fetal loss. Additionally, translocations and deletions are recognized as major genetic changes that are causally involved in neoplasia. Chromosomal variants such as deletions and inversions are exploited commonly as genetic tools in organisms such as Drosophila. Mice with defined regions of segmental haploidy are useful for genetic screening and allow accurate models of human chromosomal diseases to be generated.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: June 20, 2000
    Inventors: Allan Bradley, Ramiro Ramirez-Solis, Pentao Liu, Hong Su, Binhai Zheng
  • Patent number: 6068975
    Abstract: This invention provides an isolated, vertebrate nucleic acid molecule encoding the normal protein that prevents development of Wilson's disease. This invention also provides a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the above-described nucleic acid molecule. Finally, this invention provides various uses of the isolated Wilson's disease gene.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: May 30, 2000
    Assignees: The Trustees of Columbia University in the City of New York, General Hospital Corporation
    Inventors: T. Conrad Gilliam, Rudolph E. Tanzi